After Rexahn announced a restructuring aimed at reducing overall operating costs and prioritizing resources towards leading assets RX-3117 and RX-5902, H.C. Wainwright analyst Joseph Pantginis noted that he believes the company's recently announced safety and efficacy data from its ongoing Phase 2a trial testing RX-3117 in combination with Abraxane were "impressive, especially considering the comparison" with the current standard of care. The analyst, who thinks the stock's current valuation represents a "significant disconnect" to the underlying opportunity for the company's " promising oncology pipeline," keeps a Buy rating on Rexahn shares with a $17 price target.